Immunoassay interference is any substance or condition that causes a blood test to report a value that does not reflect the true amount of the target molecule in a patient’s sample. The consequences range from mildly confusing repeat tests to genuinely dangerous misdiagnoses, including unnecessary chemotherapy and unwarranted surgeries. Interference can push results falsely high or falsely low depending on the mechanism, the assay design, and the particular substance involved. Because immunoassays underpin a huge share of modern laboratory medicine, from thyroid panels and pregnancy tests to tumor markers and drug monitoring, understanding what can go wrong with them matters for clinicians, patients, and anyone trying to make sense of a lab result that does not match the clinical picture.
How Your Own Antibodies Can Fool the Test
Immunoassays work by using antibodies to grab and measure a target molecule. The problem is that patients have their own circulating antibodies, and some of those antibodies can latch onto the test’s reagent antibodies instead. These interfering antibodies are broadly called heterophilic antibodies. They are natural, polyreactive antibodies or autoantibodies that can bridge the assay’s capture and detection antibodies, mimicking the signal that the target molecule would produce. The result is usually a falsely elevated reading, though falsely low values also occur depending on where in the reaction the interference happens.1PubMed Central. Interferences in immunoassay
One well-known subtype is human anti-mouse antibodies, or HAMA, which develop in people who have been exposed to mouse-derived proteins through diagnostic imaging, certain therapies, or even pet ownership. But the picture is more complicated than textbooks sometimes suggest. Research has found that human anti-bovine IgG antibodies are extremely common, with a prevalence around 95% in the population studied, and that these bovine-directed antibodies can cross-react with the mouse antibodies used in two-site immunoassays. In other words, what looks like HAMA interference may often be driven by antibodies originally raised against cow proteins.2PubMed. High prevalence of human anti-bovine IgG antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies
Rheumatoid factor adds another layer. RF is an autoantibody found in many people with rheumatoid arthritis, and it has a strong tendency to bind the animal-derived antibodies used in immunoassays. In a study of an early arthritis cohort, RF-positive patients showed considerably stronger reactivity toward mouse IgG1 and rabbit IgG compared to RF-negative controls. When those high-reactivity samples were run through commercial assays, interference showed up in a meaningful fraction: roughly one in five samples tested in a beta-hCG assay, and the majority of samples tested in a multiplex cytokine panel, gave falsely elevated results.3PubMed Central. Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort This means that patients with RA are at heightened risk for misleading lab values across a wide range of tests, not just rheumatology-specific ones.4PubMed. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor
The Biotin Problem
Biotin, also known as vitamin B7, is a water-soluble vitamin found in many over-the-counter supplements marketed for hair, skin, and nail health. It also happens to be a key component in a large number of immunoassay platforms, which use biotin-streptavidin chemistry to anchor the test’s reagent antibodies. When a patient has high levels of biotin circulating in their blood, the excess biotin competes with the assay’s own biotin-labeled reagents, effectively jamming the system.
The direction of the error depends on the assay format. In competitive assays, which are commonly used for small hormones like free T4, excess biotin tends to push results falsely high. In sandwich assays, which are used for larger molecules like thyroglobulin and tumor markers, the opposite typically happens, producing falsely low results. At very high biotin levels, above roughly 500 ng/mL, one study documented a 20% change in assay values, with false-low results for thyroglobulin and alpha-fetoprotein and false-high results for anti-thyroglobulin antibodies and free T4.5PubMed Central. Biotin interference in routine clinical immunoassays
The real clinical concern has been people taking high-dose biotin, in the range of 100 to 300 mg daily, for conditions like multiple sclerosis or simply for cosmetic purposes. At those doses, biotin interference has been documented across thyroid markers, hormones, cancer markers, cardiac biomarkers, and drug assays.6PubMed. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: An emerging threat Standard multivitamin doses of biotin (around 30 micrograms) are generally too low to cause trouble, but supplements labeled for hair growth often contain 5,000 to 10,000 micrograms, and those are enough to produce meaningful interference in susceptible assays. The practical advice is simple: if you take a biotin supplement, tell your doctor before any blood work, and ideally stop taking it for a couple of days beforehand.
Macroprolactin and Hidden Immune Complexes
Sometimes the target molecule itself is the source of the problem. Prolactin, a hormone involved in lactation and reproductive function, can bind to IgG antibodies in the bloodstream, forming a large complex known as macroprolactin. This complex is biologically inert because it cannot bind to prolactin receptors, and the kidneys clear it much more slowly than free prolactin, so it accumulates.7PubMed Central. Macroprolactin; A Frequent Cause of Misdiagnosed Hyperprolactinemia in Clinical Practice The result is a blood test showing high prolactin levels in a patient who has no symptoms of excess prolactin and no pituitary tumor.
Macroprolactin remains reactive to varying degrees across all prolactin immunoassays, meaning the test detects it but the body does not respond to it.8PubMed. Determination of prolactin: the macroprolactin problem This discrepancy leads to unnecessary MRI scans, endocrine referrals, and sometimes medication in an estimated 4 to 10% of women investigated for elevated prolactin.9Annals of Laboratory Medicine. Hormone Immunoassay Interference: A 2021 Update Most labs can screen for macroprolactin using a simple precipitation step with polyethylene glycol, but the test has to be specifically requested or reflexed. If your prolactin level comes back elevated and you feel fine, macroprolactin is one of the first things to rule out.
The Hook Effect and Very High Analyte Levels
This interference is counterintuitive: a patient with an extremely high level of a substance can get a result that reads as normal or even low. In a sandwich immunoassay, the target molecule is supposed to be captured between two antibodies like the filling in a sandwich. But when the target is present in massive excess, it saturates both the capture and detection antibodies independently, preventing the sandwich from forming properly. The signal paradoxically drops.
The hook effect most often matters in contexts where analyte concentrations can spike to very high levels, such as hCG in molar pregnancies or prolactin in large pituitary tumors. The giveaway is that diluting the sample produces a dramatically higher result, because the diluted sample brings the concentration back into the assay’s working range.10PubMed. Antigen excess in modern immunoassays: to anticipate on the unexpected If a clinician suspects a very high analyte level but the result comes back unexpectedly low, requesting a dilution is the standard next step.
Cross-Reactivity From Drugs and Structurally Similar Molecules
Antibodies used in immunoassays are selected to bind a specific target, but they are not perfectly specific. Molecules that look structurally similar to the target can also bind, contributing to the measured signal. This is cross-reactivity, and it is especially relevant in steroid hormone testing and therapeutic drug monitoring.
For steroid hormones, the problem is that many steroids share a common backbone. Prednisolone can cross-react with cortisol assays. Methyltestosterone can interfere with testosterone measurements. Endogenous compounds like 21-deoxycortisol, which accumulates in certain adrenal conditions, can significantly inflate cortisol readings.11PubMed Central. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction For therapeutic drug monitoring, the same principle applies: metabolites, over-the-counter medications, and even illicit drugs can bind the assay antibodies if their molecular shape is close enough to the target drug.12PubMed Central. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays
Herbal supplements create a surprisingly potent version of this problem. Asian ginseng, Siberian ginseng, and ashwagandha all contain glycosides that are structurally similar to digoxin, a heart medication with a narrow therapeutic window. In laboratory experiments, supplementing drug-free serum with ginseng extract produced detectable apparent digoxin concentrations on some assay platforms, even though no digoxin was present.13PubMed Central. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay When ginseng extract was added to serum from patients actually taking digoxin, values swung in both directions depending on the assay platform: one platform showed nearly a 50% false increase, while another showed a false decrease.14American Journal of Clinical Pathology. Effect of Asian and Siberian Ginseng on Serum Digoxin Measurement by Five Digoxin Immunoassays: Significant Variation in Digoxin-Like Immunoreactivity Among Commercial Ginsengs For a patient on digoxin, where the difference between a therapeutic and a toxic dose is small, a false reading in either direction could lead to dose adjustments that do real harm.
Sample Condition and Collection Tubes
Not all interference comes from the patient’s biology. The sample itself can be the source. Hemolysis (red blood cells breaking apart in the tube), lipemia (milky serum from high fat content), and icterus (yellow serum from high bilirubin) are classic pre-analytical interferents. A systematic evaluation found that hemolysis affected several common immunoassays, including C-peptide, estradiol, folate, free T4, insulin, and vitamin B12, across a range of hemoglobin concentrations. Icterus interfered with BNP, estradiol, free T3, and homocysteine assays. Lipemia altered results for BNP, folate, and homocysteine.15PubMed. Evaluation of hemolysis, lipemia, and icterus interference with common clinical immunoassays
Even the blood collection tubes themselves can cause trouble. Components like stoppers, lubricants, surfactants, and separator gels can leach into specimens or adsorb analytes out of the sample.16PubMed Central. Interferences from blood collection tube components on clinical chemistry assays One surfactant commonly used in separator-gel tubes, Pluronic F-127, has been shown to increase the rate at which antigen-antibody complexes fall apart, meaning the surfactant actively weakens the binding that the assay depends on.17Journal of Laboratory and Precision Medicine. Blood collection device components: issues, innovations, and recommendations for clinical laboratories and manufacturers—a narrative review This kind of interference is invisible to the clinician ordering the test and hard for the lab to catch unless it is specifically investigated.
Biologic Therapies and Genetic Variants
The growing use of monoclonal antibody drugs has introduced a relatively new source of interference. These therapeutic antibodies are human or humanized immunoglobulins, and they can show up on electrophoresis and immunofixation tests as monoclonal bands that mimic the signature of a blood cancer. In one published case, a patient being treated for multiple myeloma developed a new IgG kappa band on immunofixation. The band initially raised concern about a second malignancy, but it turned out to be denosumab, a monoclonal antibody prescribed to treat her bone lesions. The band disappeared months after the last dose, confirming it was drug interference.18PubMed. Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring: a Denosumab Experience As more monoclonal antibody therapies enter routine use, this type of confusion is expected to become more common.
Genetics can also play a role. Familial dysalbuminaemic hyperthyroxinaemia, or FDH, is a condition caused by a mutation in the albumin gene that changes how albumin binds thyroid hormones. People with FDH are clinically euthyroid — their thyroid function is perfectly normal — but their free thyroid hormone levels read as artificially elevated on many immunoassay platforms.19PubMed Central. Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods Without awareness of this condition, patients can be incorrectly diagnosed with hyperthyroidism and started on unnecessary treatment. FDH is inherited, so it often runs in families and can cause diagnostic confusion across generations.
Real-World Harm From Unrecognized Interference
The stakes of missed interference are not abstract. The term “phantom hCG” describes persistently positive pregnancy hormone levels in a patient who is not pregnant. These false positives have led to diagnoses of gestational trophoblastic disease (a type of cancer) and subsequent treatment with chemotherapy or hysterectomy in women who had no malignancy at all.20PubMed Central. A rational diagnostic approach to the “phantom hCG” and other clinical scenarios in which a patient is thought to be pregnant but is not The interfering substance in these cases is typically a heterophilic antibody that generates a positive signal on the hCG assay.
In another documented case, immunoassay interference in aldosterone measurement led a patient to the point of being scheduled for adrenal gland surgery. Mass spectrometry testing revealed that the immunoassay had been overreading the aldosterone concentration by roughly ninefold. The immunoassay values dropped to match the mass spectrometry values only after sample purification to remove large molecules, confirming that an interfering macromolecule had been responsible.21PubMed. Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference The surgery was cancelled. These are not fringe anecdotes; they reflect the reality that immunoassay interference can redirect the entire trajectory of patient care.
How Labs Detect and Resolve Interference
Suspecting interference is the hardest part. Once it is considered, labs have several tools. The most common initial step is serial dilution: if a result does not drop proportionally when the sample is diluted, something other than the target analyte is contributing to the signal. Another approach is treating the sample with heterophile blocking reagent, a commercially available additive that mops up interfering antibodies, then re-running the test. If the result changes substantially after blocking, interference is confirmed.22PubMed Central. Interferences in immunoassay Labs may also test the same sample on a different manufacturer’s assay platform, since interference is often platform-specific.23Clinical Chemistry. Screening for Interference in Immunoassays
When the question is serious enough, mass spectrometry serves as the definitive referee. Unlike immunoassays, which rely on antibody-target binding, mass spectrometry identifies molecules by their physical mass and fragmentation pattern, making it essentially immune to the types of interference that plague antibody-based tests. Liquid chromatography–tandem mass spectrometry has been developed and validated as an arbiter for discordant immunoassay results in several hormones, including ACTH and testosterone.24Clinical Chemistry. An Intact ACTH LC-MS/MS Assay as an Arbiter of Clinically Discordant Immunoassay Results In a recent case of apparent hyperandrogenism in a woman, an immunoassay reported elevated testosterone, but mass spectrometry confirmed the value was within normal limits, resolving the discrepancy as assay interference.25JCEM Case Reports. Apparent Hyperandrogenemia Due to Immunoassay Interference Resolved by Liquid Chromatography–Tandem Mass Spectrometry
Mass spectrometry is not practical for every routine test — it requires expensive equipment, specialized expertise, and more processing time. But for steroid hormones, therapeutic drugs, and situations where clinical suspicion and lab results simply do not match, it is increasingly the gold standard for settling the question.
Assay Design Is Evolving to Fight Back
Manufacturers are not standing still. One approach is to engineer the assay’s antibodies to be inherently less susceptible to interference. Traditional immunometric assays use whole monoclonal antibodies as capture reagents, and these intact immunoglobulins present the Fc region that heterophilic antibodies love to grab. Researchers have tested single-chain antibody fragments, which lack the Fc region entirely, as replacements. In assays for carcinoembryonic antigen (a tumor marker), switching to a recombinant single-chain antibody as the capture reagent reduced heterophilic antibody interference compared to assays using whole immunoglobulin, even without adding blocking agents to the reaction buffer.26Clinical Chemistry. Use of an In Vivo Biotinylated Single-Chain Antibody as Capture Reagent in an Immunometric Assay to Decrease the Incidence of Interference from Heterophilic Antibodies
Newer reagent formulations have also raised the bar for biotin and sample-matrix interference. Testing of a light-initiated chemiluminescent assay for testosterone, following current Clinical and Laboratory Standards Institute protocols, showed robust resistance against hemoglobin, biotin, triglycerides, and bilirubin up to specified non-interfering thresholds.27PubMed Central. Application of the latest CLSI EP guidelines in light-initiated chemiluminescent assay for testosterone The trend is toward platform-level solutions that make interference less likely rather than relying solely on clinicians and lab workers to catch it after the fact. But no assay design eliminates all interference, and the human step of recognizing when a result does not fit the patient remains irreplaceable.
When to Suspect Interference as a Patient
You cannot diagnose immunoassay interference on your own, but you can recognize the situations where it is worth raising the question. The biggest red flag is a lab result that contradicts how you actually feel. An elevated prolactin when you have no symptoms. A positive pregnancy test when pregnancy is impossible. A thyroid panel suggesting hyperthyroidism when your energy, weight, and heart rate are all normal. A sudden, unexplained jump in a tumor marker that had been stable.
Certain patient characteristics increase the risk. If you have rheumatoid arthritis or another autoimmune condition, your RF and other autoantibodies make you more susceptible to heterophilic interference. If you have received mouse-derived antibodies for imaging or treatment, you may have developed HAMA. If you take high-dose biotin supplements, your thyroid and cardiac marker results may be unreliable. If you take herbal supplements containing ginseng or ashwagandha and you are also on digoxin, your drug levels may read incorrectly.
The most productive thing you can do is give your doctor a complete list of every supplement and medication you take, including over-the-counter products, and mention any prior exposure to monoclonal antibody therapies or diagnostic procedures involving animal-derived proteins. When a result does not make sense, the fix is usually straightforward: repeat the test on a different platform, run a dilution, add a blocking reagent, or send the sample for mass spectrometry confirmation. The interference itself is often harmless. The danger comes from acting on a result without questioning it.